Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
18 July 2019Website:
http://www.fulcrumtx.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 25 Jun 2024 20:08:24 GMTDividend
Analysts recommendations
Institutional Ownership
FULC Latest News
The average price target suggests a potential 69.2% increase for Fulcrum Therapeutics (FULC). Although studies have shown this metric may not always be accurate, an increase in earnings estimates could indicate a positive outlook for the stock in the near future.
Fulcrum Therapeutics, Inc. (FULC) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.50 per share a year ago.
Fulcrum Therapeutics, Inc. (FULC) Q4 2023 Earnings Call Transcript
Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Chris Calabrese - LifeSci Advisors, LLC Alex Sapir - President and Chief Executive Officer Alan Musso - Chief Financial Officer Iain Fraser - Interim Chief Medical Officer Conference Call Participants Benazir Ali - Stifel Joe Schwartz - Leerink Partners Edward Tenthoff - Piper Sandler Matthew Hagood - Oppenheimer Operator Good morning and welcome to Fulcrum Therapeutics Third Quarter 2023 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode.
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third quarter 2023 financial results will be released on Tuesday, November 7, 2023 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Fulcrum Therapeutics, Inc. has had some key potential catalysts resolved positively recently. These included the FDA lifted the clinical hold on Fulcrum's sickle-cell disease candidate, allowing the company's Phase 1b trial to move forward. The company has also made progress in filling management positions and has initiated a Phase 3 study for its late-stage candidate, Losmapimod.
Fulcrum's (FULC) shares surge as the FDA lifts the clinical hold it had earlier placed on its pipeline candidate FTX-6058, to treat patients with sickle cell disease.
Fulcrum Therapeutics Inc (NASDAQ:FULC) is up 49.7% to trade at $5.87 at last glance -- its highest levels since March -- after the U.S. Food and Drug Administration (FDA) lifted its clinical hold on the biotech name's application for its sickle cell disease treatment.
Fulcrum Therapeutics (NASDAQ: FULC ) stock is on the rise Tuesday as investors react to positive news from the FDA. The big news here is the FDA lifted its clinical hold on the Investigational New Drug (IND) application for FTX-6058.
Fulcrum Therapeutics announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug (IND) application for its sickle cell disease therapeutic FTX-6058, sending its shares almost 40% higher in pre-market trading.
What type of business is Fulcrum Therapeutics?
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What sector is Fulcrum Therapeutics in?
Fulcrum Therapeutics is in the Healthcare sector
What industry is Fulcrum Therapeutics in?
Fulcrum Therapeutics is in the Biotechnology industry
What country is Fulcrum Therapeutics from?
Fulcrum Therapeutics is headquartered in United States
When did Fulcrum Therapeutics go public?
Fulcrum Therapeutics initial public offering (IPO) was on 18 July 2019
What is Fulcrum Therapeutics website?
https://www.fulcrumtx.com
Is Fulcrum Therapeutics in the S&P 500?
No, Fulcrum Therapeutics is not included in the S&P 500 index
Is Fulcrum Therapeutics in the NASDAQ 100?
No, Fulcrum Therapeutics is not included in the NASDAQ 100 index
Is Fulcrum Therapeutics in the Dow Jones?
No, Fulcrum Therapeutics is not included in the Dow Jones index
When does Fulcrum Therapeutics report earnings?
The next expected earnings date for Fulcrum Therapeutics is 02 August 2024